Scientists may have sniffed out a breakthrough when detecting Alzheimer’s. The degenerative disease, which affects millions ...

A new study suggests that two of Alzheimer’s disease’s most debated players may be more closely connected than they first ...

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

Hong Kong University of Science and Technology (HKUST) on Monday launched a five-year scheme offering free screenings ...

Science rarely hands us plot twists this dramatic—where two of the most feared diseases of our time, cancer and Alzheimer’s, ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), reports a new study at Columbia ...

At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, Eli Lilly and Company presented new data evaluating the ...

Former KQRS Morning Show host Tom Barnard announced on his podcast that he has been undergoing treatment for Alzheimer's.

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...